Next Gen Biotech

Spegra Tablet contains the active ingredients Dolutegravir, Emtricitabine, and Tenofovir Alafenamide. It is a combination of antiretroviral medication. Dolutegravir belongs to a class of antiretroviral drugs called integrase strand transfer inhibitors (INSTIs). Emtricitabine belongs to the class of medication called nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide belongs to the class called nucleotide reverse transcriptase inhibitor (NtRTI). It is combined with other medicines to treat human immunodeficiency virus (HIV-1) infection in adults and adolescents 12 years of age who weigh at least 35kg. 

The combination is available as a single tablet regimen, simplifying treatment by reducing the number of pills a person must take daily. This convenience improves medication adherence, ensuring individuals can consistently take their prescribed medication as scheduled. Do not take Spegra Tablet if anyone is allergic to it or its components. Get tested for HIV infection regularly while using this medicine. Missing a dose increases the risk of getting HIV infection. This medicine does not prevent other sexually transmitted infections (STIs). Patients should inform the physician if they have liver problems or liver disease, including hepatitis, kidney, and bone problems. This HIV medication is not recommended to give in to children aged 11 years or under.